<DOC>
	<DOCNO>NCT01965509</DOCNO>
	<brief_summary>Polyethylene Glycol Loxenatide ( PEX168 ) new human glucagon-like peptide 1 ( GLP-1 ) analogue create basis Exenatide modify polyethylene glycol ( PEG ) . This study aim evaluate effective therapeutic concentration range PEX168 , also decide observe safety PK/PD correlation long-term continuous administration .</brief_summary>
	<brief_title>A PK/PD Study Polyethylene Glycol Loxenatide Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Has diagnose type 2 diabetes mellitus . 2 . Has treat stable dose metformin monotherapy ≥ 12 week randomization , metformin dose ≥ 1500 mg / day . 3 . Has HbA1c 7.5 % 11.0 % ( local ) screening . And HbA1c 7.0 % 11.0 % ( Central ) randomization . 4 . Is 20 70 year old , inclusive . 5 . Has body mass index ( BMI ) 19 kg/m2 35 kg/m2 , inclusive . 1 . Skin test PEX168 positive . 2 . Is currently treat follow excluded medication : GLP1 GLP1 analogues prior study start ; Insulin within 6 month prior study start ; Growth hormone within 6 month prior study start ; Abuse drug alcohol within 6 month prior study start ; Any hypoglycemic drug ( include Chinese herbal medicine ) except metformin within 3 month prior study start ; Any clinical trial drug medical instrument within 3 month prior study start ; Systemic corticosteroid oral , parenteral , intraarticular route Any drug weight loss operation lead weight instable within 2 month prior study start ; Any drug may interfere evaluation safety efficiency investigate drug , drug herbal medicine may result toxicity main organ prior study start ; 3 . A history evidence follow : Severe hypoglycemia history ( e.g. , sleepiness , consciousness disorder , deliration , coma lead hypoglycemia ) ; Type 1 diabetes , monogenic diabetes , diabetes result pancreatic injury , secondary form diabetes ( e.g. , Cushing 's syndrome acromegalyassociated diabetes ) ; Acute chronic gastrointestinal disease suitable trial evaluate investigator ; Hypertension SBP &gt; 140mmHg , and/or DBP &gt; 90mmHg antihypertensive therapy ; Severe cardiovascular disease history include congestive heart failure ( NYHA III IV ) , unstable angina , stroke TIA , myocardial infarction , sustain clinically relevant ventricular arrhythmia , coronary artery bypass surgery percutaneous coronary intervention ; Acute chronic pancreatitis history , pancreas injury history , high risk factor may result pancreatitis ; Malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , regardless whether evidence local recurrence metastasis ; Medullary thyroid carcinoma history , multiple endocrine neoplasia history ; Acute metabolic complication ketoacidosis , lactic acidosis , hyperosmolar state ( coma ) , maculopathy , instability proliferative retinopathy within past 6 month ; Weight change 10 % within 3 month prior study start ; 4 . Any following significant laboratory abnormality : Alanine aminotrasferase ( ALT ) and/or asparatate aminotransferase ( AST ) &gt; 2*upper limit normal ( ULN ) , and/or total bilirubin &gt; 1.5*ULN , confirm repeat measure ; Creatinine &gt; upper limit normal , confirm repeat measure , and/or proteinurea &gt; ++ 24 hour urinary protein quantitative ≥1g ; Fasting plasma triglyceride ≥ 5.64 mmol/L ( 500mg/dL ) ; Thyroid dysfunction unsuitable trial evaluate investigator ; Hemodlastase &gt; upper limit normal , confirm repeat measure ; 5 . Male female fertility reluctant take contraceptive method test , pregnancy lactate woman ; 6 . Any situation may result withdrawal subject bring significant risk subject .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>PEX168</keyword>
	<keyword>Phase I/II</keyword>
	<keyword>add metformin</keyword>
</DOC>